Authors:
Bast, RC
Ravdin, P
Hayes, DF
Bates, S
Fritsche, H
Jessup, JM
Kemeny, N
Locker, GY
Mennel, RG
Somerfield, MR
Citation: Rc. Bast et al., 2000 update of recommendations for the use of tumor markers in breast and colorectal cancer: Clinical practice guidelines of the American Society of Clinical Oncology, J CL ONCOL, 19(6), 2001, pp. 1865-1878
Authors:
Bast, RC
Ravdin, P
Hayes, DF
Bates, S
Fritsche, H
Jessup, JM
Kemeny, N
Locker, GY
Mennel, RG
Somerfield, MR
Citation: Rc. Bast et al., 2000 update of recommendations for the use of tumor markets in breast and colorectal cancer: Clinical practice guidelines for the American Society ofClinical Oncology (vol 19, pg 1865, 2001), J CL ONCOL, 19(21), 2001, pp. 4185-4188
Authors:
Kemeny, N
Gonen, M
Sullivan, D
Schwartz, L
Benedetti, F
Saltz, L
Stockman, J
Fong, Y
Jarnagin, W
Bertino, J
Tong, W
Paty, P
Citation: N. Kemeny et al., Phase I study of hepatic arterial infusion of floxuridine and dexamethasone with systemic irinotecan for unresectable hepatic metastases from colorectal cancer, J CL ONCOL, 19(10), 2001, pp. 2687-2695
Citation: N. Kemeny et al., Hepatic arterial infusion of chemotherapy for metastatic colorectal cancer- Reply, N ENG J MED, 342(20), 2000, pp. 1526-1527
Authors:
Banerjee, D
Gorlick, R
Liefshitz, A
Danenberg, K
Danenberg, PC
Danenberg, PV
Klimstra, D
Jhanwar, S
Cordon-Cardo, C
Fong, Y
Kemeny, N
Bertino, JR
Citation: D. Banerjee et al., Levels of E2F-1 expression are higher in lung metastasis of colon cancer as compared with hepatic metastasis and correlate with levels of thymidylatesynthase, CANCER RES, 60(9), 2000, pp. 2365-2367
Authors:
Fata, F
Ron, IG
Maluf, F
Klimstra, D
Kemeny, N
Citation: F. Fata et al., Intra-abdominal fibrosis after systemic and intraperitoneal therapy containing fluoropyrimidines, CANCER, 88(11), 2000, pp. 2447-2451
Authors:
Kemeny, N
Huang, Y
Cohen, AM
Shi, WJ
Conti, JA
Brennan, MF
Bertino, JR
Turnbull, ADM
Sullivan, D
Stockman, J
Blumgart, LH
Fong, YM
Citation: N. Kemeny et al., Hepatic arterial infusion of chemotherapy after resection of hepatic metastases from colorectal cancer., N ENG J MED, 341(27), 1999, pp. 2039-2048
Authors:
Fong, YM
Saldinger, PF
Akhurst, T
Macapinlac, H
Yeung, H
Finn, RD
Cohen, A
Kemeny, N
Blumgart, LH
Larson, SM
Citation: Ym. Fong et al., Utility of F-18-FDG positron emission tomography scanning on selection of patients for resection of hepatic colorectal metastases, AM J SURG, 178(4), 1999, pp. 282-287
Authors:
Saltz, LB
Spriggs, D
Schaaf, LJ
Schwartz, GK
Ilson, D
Kemeny, N
Kanowitz, J
Steger, C
Eng, M
Albanese, P
Semple, D
Hanover, CK
Elfring, GL
Miller, LL
Kelsen, D
Citation: Lb. Saltz et al., Phase I clinical and pharmacologic study of weekly cisplatin combined withweekly irinotecan in patients with advanced solid tumors, J CL ONCOL, 16(12), 1998, pp. 3858-3865